Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Lowered to $52.00 at UBS Group

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Rating) had its price objective trimmed by UBS Group to $52.00 in a research note published on Monday, Stock Target Advisor reports.

A number of other equities analysts have also recently issued reports on ZNTL. Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a research report on Monday, November 14th. Guggenheim decreased their price target on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a buy rating for the company in a research report on Friday, November 11th. Wedbush decreased their price target on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an outperform rating for the company in a research report on Monday, November 14th. HC Wainwright decreased their price target on shares of Zentalis Pharmaceuticals from $120.00 to $55.00 and set a buy rating for the company in a research report on Wednesday, August 10th. Finally, Morgan Stanley decreased their price target on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an overweight rating for the company in a research report on Friday, November 11th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of Buy and a consensus price target of $46.56.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $21.12 on Monday. The company has a 50 day simple moving average of $22.67 and a 200 day simple moving average of $25.18. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -4.47 and a beta of 1.90. Zentalis Pharmaceuticals has a 1 year low of $17.33 and a 1 year high of $85.95.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the company’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $22.32, for a total transaction of $279,000.00. Following the transaction, the president now owns 431,885 shares in the company, valued at $9,639,673.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 62,500 shares of company stock worth $1,469,125. Insiders own 19.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors raised its holdings in shares of Zentalis Pharmaceuticals by 15,160.0% in the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after purchasing an additional 758 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Zentalis Pharmaceuticals by 337.3% in the second quarter. Assetmark Inc. now owns 1,054 shares of the company’s stock valued at $30,000 after purchasing an additional 813 shares during the last quarter. US Bancorp DE increased its holdings in Zentalis Pharmaceuticals by 378.9% during the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after buying an additional 1,148 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Zentalis Pharmaceuticals during the first quarter worth about $72,000. Finally, Great West Life Assurance Co. Can bought a new position in Zentalis Pharmaceuticals during the third quarter worth about $48,000.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Read More

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.